0000899243-18-006817.txt : 20180308
0000899243-18-006817.hdr.sgml : 20180308
20180308163854
ACCESSION NUMBER: 0000899243-18-006817
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20180306
FILED AS OF DATE: 20180308
DATE AS OF CHANGE: 20180308
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Tulipano Stephen J
CENTRAL INDEX KEY: 0001360548
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36332
FILM NUMBER: 18676996
MAIL ADDRESS:
STREET 1: C/O JAVELIN PHARMACEUTICALS, INC.
STREET 2: 125 CAMBRIDGE PARK DRIVE
CITY: CAMBRIDGE
STATE: MA
ZIP: 02140
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Aldeyra Therapeutics, Inc.
CENTRAL INDEX KEY: 0001341235
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 131 HARTWELL AVENUE
STREET 2: SUITE 320
CITY: LEXINGTON
STATE: MA
ZIP: 02421
BUSINESS PHONE: 781-761-4904
MAIL ADDRESS:
STREET 1: 131 HARTWELL AVENUE
STREET 2: SUITE 320
CITY: LEXINGTON
STATE: MA
ZIP: 02421
FORMER COMPANY:
FORMER CONFORMED NAME: Aldexa Therapeutics, Inc.
DATE OF NAME CHANGE: 20130102
FORMER COMPANY:
FORMER CONFORMED NAME: Neuron Systems Inc
DATE OF NAME CHANGE: 20051012
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2018-03-06
0
0001341235
Aldeyra Therapeutics, Inc.
ALDX
0001360548
Tulipano Stephen J
C/O ALDEYRA THERAPEUTICS, INC.
131 HARTWELL AVENUE
LEXINGTON
MA
02421
0
1
0
0
Chief Financial Officer
Common Stock
2017-06-30
5
A
0
E
2077
3.9525
A
5410
D
Common Stock
2017-12-29
5
A
0
E
3153
3.995
A
8563
D
Employee Stock Option (Right to Buy)
8.60
2018-03-06
4
A
0
125670
0.00
A
2028-03-05
Common Stock
125670
125670
D
Represents the voluntary reporting of 2,077 shares of common stock acquired under the Issuer's Employee Stock Purchase Plan (ESPP) in June 2017.
In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the Issuer's common stock on June 30, 2017.
Represents the voluntary reporting of 3,153 shares of common stock acquired under the Issuer's ESPP in December 2017.
In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the Issuer's common stock on July 3, 2017.
The shares subject to this option shall vest in equal monthly installments over the next 48 months of continuous service to the Issuer after January 1, 2018.
/s/ Stephen Tulipano
2018-03-08